18 Facts About Wyeth

Wyeth was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother.

Wyeth manufactured over-the-counter drugs Robitussin and the analgesic Advil as well as prescription drugs Premarin and Effexor.

In 1860, pharmacists John and Frank Wyeth opened a drugstore with a small research lab on Walnut Street in Philadelphia.

In 1872, Henry Bowers, an employee of Wyeth, developed one of the first rotary compressed tablet machines in the United States.

In 1883, Wyeth opened its first international facility in Montreal, Canada, and began vaccine production.

Related searches

John Wyeth died in 1907 and his only son, Stuart, became the company's president.

In 1929, Stuart Wyeth died and left controlling interest to Harvard University.

In 1930, Wyeth purchased Anacin, a product for tension headaches which quickly became the company's flagship product.

Wyeth made its first licensing deal, acquiring an antibiotic for arthritis vaccine research.

Wyeth was later rewarded for its contribution to the war effort.

Specifically, Wyeth asserted that the BHRT drugs are not licensed by the FDA according to section 505 of the Food, Drug and Cosmetic Act, misbranded and adulterated per sections 501 and 502 of 21 U S C .

In 2003 Wyeth reportedly contributed funds to a not-for-profit support group, The Meningitis Centre, which lobbied the Australian government to introduce universal immunisation against pneumococcal disease.

Wyeth produced the only pneumococcal vaccine approved for young children in Australia.

The purchase was approved by the SEC and went into effect later in 2009, although vestiges of Wyeth remained for another year or two while effects of the acquisition were ironed out.

In 2020, Wyeth Holdings agreed to settle a claim that stemmed from a lawsuit alleging long term environmental damages by paying $4.

Wyeth was established in Fort Dodge, Iowa, to manufacture hog cholera serum.

Wyeth is targeted in the suit for off-label marketing, targeting specific doctors and medical facilities to increased sales of Rapamune, trying to get current transplant patients to change from their current transplant drugs to Rapamune and for specifically targeting African-Americans.

Wyeth was particularly criticised by observers for its use of 'ghostwriters' to put their names to research papers that Wyeth had paid a third party, DesignWrite, to prepare.